Full Breakdown
Oxybutynin Shows Promise in Reducing Hot Flashes for Prostate Cancer Patients
2/4/2026, 10:58:38 PM
Significant Findings from Clinical Trial
A recent clinical trial has demonstrated that oxybutynin, a medication commonly used to treat overactive bladder symptoms, can significantly reduce hot flashes in men undergoing androgen deprivation therapy (ADT) for prostate cancer. The study, published in the *Journal of Clinical Oncology*, involved 81 men with an average age of 68, who reported experiencing at least 28 hot flashes per week. Participants were randomly assigned to receive either a placebo or one of two doses of oxybutynin (2.5 mg or 5 mg) twice daily over a six-week period.
The results indicated that men taking the higher dose of oxybutynin experienced an average reduction of 6.89 hot flashes per day, compared to a reduction of 2.15 in the placebo group. Additionally, the oxybutynin groups reported significant decreases in hot flash severity scores, with the 5 mg group showing a 13.95-point reduction compared to just 4.85 points in the placebo group.
Background on Hormone Therapy and Hot Flashes
Hormone therapy is an effective treatment for prostate cancer, as it lowers testosterone levels that fuel cancer cell growth. However, it can lead to hot flashes in up to 80% of patients, causing fatigue and sleep disturbances that may lead to discontinuation of treatment. Previous studies have shown that oxybutynin can alleviate hot flashes in women, prompting researchers to explore its potential benefits for men undergoing ADT.
Official Statements & Responses
Dr. Bradley Stish, the lead researcher from the Mayo Clinic, emphasized the importance of these findings, stating, “Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer.” He noted that the results provide strong support for oxybutynin as an effective management option for this often-overlooked side effect.
Criticism & Opposition
While the study's findings are promising, some experts have pointed out that the placebo group also experienced improvements, suggesting a possible placebo effect. Additionally, the trial's small sample size raises questions about the generalizability of the results. Larger studies are needed to confirm these findings and determine optimal dosing.
What's Next
Future research will focus on further understanding hot flash management options for prostate cancer patients. Dr. Stish indicated that additional studies are necessary to explore the long-term effects and efficacy of oxybutynin in diverse populations.
Verbatim Quotes
- “These results are incredibly encouraging,” — Dr. Bradley Stish, Radiation Oncologist, Mayo Clinic
- “oxybutynin demonstrated a sustained, significant decrease in hot flash frequency, without serious treatment-related side effects,” — Study Authors
The findings from this trial represent a significant advancement in the management of hot flashes for men undergoing hormone therapy for prostate cancer, offering a new therapeutic option to improve their quality of life.
